[{"address1": "Gemenskapens gata 9", "city": "M\u00f6lndal", "zip": "431 53", "country": "Sweden", "phone": "46 3 17 88 21 50", "website": "https://www.xvivogroup.com", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in M\u00f6lndal, Sweden.", "fullTimeEmployees": 152, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christoffer  Rosenblad", "age": 48, "title": "Chief Executive Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kristoffer  Nordstrom", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1985, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lena  Hagman B.Sc.", "age": 58, "title": "Chief Operating Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ylva  Vihoj", "age": 53, "title": "Global Human Resources Director", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Magnus  Nilsson Ph.D.", "age": 67, "title": "Senior Advisor", "yearBorn": 1956, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andreas  Wallinder M.D., Ph.D.", "age": 46, "title": "Chief Medical Officer", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Johan  Holmstrom", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 49.67, "open": 49.67, "dayLow": 49.4, "dayHigh": 49.67, "regularMarketPreviousClose": 49.67, "regularMarketOpen": 49.67, "regularMarketDayLow": 49.4, "regularMarketDayHigh": 49.67, "beta": 2.097, "trailingPE": 126.66667, "volume": 300, "regularMarketVolume": 300, "averageVolume": 97, "averageVolume10days": 94, "averageDailyVolume10Day": 94, "bid": 46.8, "ask": 48.24, "bidSize": 40000, "askSize": 40000, "marketCap": 1556075392, "fiftyTwoWeekLow": 19.9, "fiftyTwoWeekHigh": 52.3768, "priceToSalesTrailing12Months": 2.2270212, "fiftyDayAverage": 46.79819, "twoHundredDayAverage": 34.012398, "currency": "USD", "enterpriseValue": 1102492800, "profitMargins": 0.17278999, "floatShares": 24995774, "sharesOutstanding": 31499500, "heldPercentInsiders": 0.10479999, "heldPercentInstitutions": 0.54223996, "bookValue": 64.28, "priceToBook": 0.7685128, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 2.949, "netIncomeToCommon": 120736000, "trailingEps": 0.39, "enterpriseToRevenue": 1.578, "enterpriseToEbitda": 16.998, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "XVIPF", "underlyingSymbol": "XVIPF", "shortName": "Xvivo Perfusion AB", "longName": "Xvivo Perfusion AB (publ)", "firstTradeDateEpochUtc": 1405949400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "98faded1-61e8-3e82-87cd-43e725d4eba9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 49.4, "recommendationKey": "none", "totalCash": 480768000, "totalCashPerShare": 15.263, "ebitda": 64860000, "totalDebt": 27187000, "quickRatio": 3.266, "currentRatio": 4.129, "totalRevenue": 698724992, "debtToEquity": 1.343, "revenuePerShare": 22.716, "returnOnAssets": 0.01317, "returnOnEquity": 0.06844, "freeCashflow": -77763000, "operatingCashflow": 69297000, "earningsGrowth": 2.739, "revenueGrowth": 0.361, "grossMargins": 0.74161005, "ebitdaMargins": 0.09283, "operatingMargins": 0.15890999, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]